Epizyme, Inc. (NASDAQ:EPZM) insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $16.81, for a total value of $252,150.00. Following the sale, the insider now directly owns 23,123 shares in the company, valued at $388,697.63. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Peter Tai-Ching Ho also recently made the following trade(s):

  • On Thursday, August 24th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The shares were sold at an average price of $15.68, for a total value of $235,200.00.
  • On Monday, July 24th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The shares were sold at an average price of $13.44, for a total value of $201,600.00.

Shares of Epizyme, Inc. (NASDAQ:EPZM) traded down 0.61% during mid-day trading on Tuesday, hitting $16.40. The stock had a trading volume of 599,273 shares. The stock’s market cap is $958.84 million. The firm has a 50 day moving average price of $15.50 and a 200-day moving average price of $15.25. Epizyme, Inc. has a 12 month low of $8.38 and a 12 month high of $20.00.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The firm had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $3.95 million. During the same period in the prior year, the business earned ($0.49) EPS. The company’s revenue for the quarter was up 2027.7% compared to the same quarter last year. On average, equities research analysts forecast that Epizyme, Inc. will post ($2.36) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/26/insider-selling-epizyme-inc-epzm-insider-sells-15000-shares-of-stock-2.html.

Several institutional investors and hedge funds have recently bought and sold shares of EPZM. Russell Investments Group Ltd. boosted its holdings in shares of Epizyme by 59.6% in the 1st quarter. Russell Investments Group Ltd. now owns 45,343 shares of the biopharmaceutical company’s stock worth $778,000 after purchasing an additional 16,924 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Epizyme by 8.2% in the 1st quarter. Bank of New York Mellon Corp now owns 196,837 shares of the biopharmaceutical company’s stock worth $3,377,000 after purchasing an additional 14,978 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new position in shares of Epizyme in the 1st quarter worth about $175,000. American International Group Inc. boosted its holdings in shares of Epizyme by 7.1% in the 1st quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock worth $425,000 after purchasing an additional 1,638 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Epizyme by 0.5% in the 1st quarter. Principal Financial Group Inc. now owns 94,173 shares of the biopharmaceutical company’s stock worth $1,615,000 after purchasing an additional 515 shares in the last quarter. Hedge funds and other institutional investors own 72.23% of the company’s stock.

Several analysts recently weighed in on EPZM shares. Leerink Swann reaffirmed an “outperform” rating and issued a $28.00 price objective (down from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Epizyme in a research note on Friday, September 15th. BidaskClub raised Epizyme from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a research note on Tuesday, September 19th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $23.33.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Insider Buying and Selling by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.